NCT00131274View on ClinicalTrials.gov

Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

April 30, 2003

Study Completion Date

August 31, 2007

Conditions

Idiopathic Pulmonary FibrosisLung DiseasePulmonary Fibrosis

Interventions

DRUG

Imatinib Mesylate (Gleevec)

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Daniels, Craig E., M.D.

INDIV

NCT00131274 - Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study | Biotech Hunter | Biotech Hunter